PTN
Palatin Technologies Inc.
Halal Rating :
Last Price
$1.04
Last updated:
Market Cap
-
7D Change
-6.31%
1 Year Change
-71.66%
Company Overview
Industries
Exchange
Next Earnings Date
Palatin Technologies Inc. is a biopharmaceutical company focused on developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Their primary product is Vyleesi®, which is FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
The company also has other melanocortin receptor agonists and natriuretic peptide receptor agonists in development for various conditions including inflammatory and autoimmune diseases.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $350000.0 | $8.75m | - | $3373.0 | 0.00% | 0.04% |
Company Impact
Help us evaluate Palatin Technologies Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.